IPX233

IPX233 is an investigational oral central nervous system (CNS) stimulant that was being developed by Impax Pharmaceuticals (now Amneal Pharmaceuticals) for the treatment of attention deficit hyperactivity disorder (ADHD). The drug was designed for once-daily administration, likely utilizing Impax's proprietary drug delivery technologies. However, clinical development appears to have been discontinued; a Phase 1 pharmacokinetic and safety study in healthy volunteers (IPX233-B14-02) was withdrawn in 2015 before enrollment began. The specific active pharmaceutical ingredient contained within the IPX233 formulation has not been disclosed in public records.